



In-Cell-Art Wins 2013 Deloitte Technology Fast 50 West Award



Nantes – France, 8th of November, 2013 – In-Cell-Art, a biotechnology company specializing in nanocarrier technologies called Nanotaxi® for macromolecules (DNA, mRNA, Protein) announced today that it won second place (745% revenue growth) in 2013 Deloitte Technology Fast 50 West.

Deloitte Technology Fast 50 Award began in 1995 in San Jose, California, in the center of Silicon Valley, and quickly spread throughout the whole United States. Then, it has expanded to twelve countries and regions such as United Kingdom, Canada, Japan and France.

Companies are ranked by percentage revenue growth over the last five years (2008-2012). To qualify, companies must own proprietary technology. Participants can be private or public companies operating in any field of technology.

Bruno Pitard, co-founder of In-Cell-Art, said “In-Cell-Art is very pleased to win Deloitte Technology Fast 50 West Award for two consecutive years (2nd in 2013 and 3rd in 2012). Those prizes are recognition of the fact that In-Cell-Art demonstrated a distinct competitive advantage in a high growth market for the last 6 years”.

“Since Deloitte Technology Fast 50 takes into account a sustained revenue growth over five years, ranking in this list of top technology companies is an achievement” said Laurent Halfon, Associé Responsable of Technology Fast 50 in Deloitte. “In-Cell-Art deserves our congratulations for this amazing growth”.

About In-Cell-Art

In-Cell-Art (ICA), which is headquartered in Nantes (France) is a biopharmaceutical company specializing in the preclinical and pharmaceutical development of nanocarriers named Nanotaxi ® for macromolecular drugs. Its founder and research team, which includes a Nobel Laureate, have designed new classes of vectors that are organized on a nanometric scale, which enables them to cross the cell barrier efficiently and safely. In-Cell-Art offers a range of reagents and biotechnology development services:

1. ICANtibodies™

In the absence of recombinant antigen, ICANtibodies™ allows, from an in silico DNA antigenic sequence, the production of the most ambitious functional antibodies

against any natively expressed nuclear, cytoplasmic, secreted or membrane proteins. ICANtibodies™ has allowed, in less than 3 years, the production of more than 300 different functional antibodies. In-Cell-Art has worked with a number of pharmaceutical firms (Sanofi, GlaxoSmithKline, Geneuro etc.) and public research institutions and universities (Institut Cochin, Cancer Research UK, Institute of Neurology UK etc).

2. ICA Nanotaxi®

- DNA Vaccine

ICA614 Nanotaxi®, an innovative DNA synthetic formulation, offers unique efficient and industrial features such as the dramatic enhancement of the immunogenicity of plasmid DNA-encoding tumours or pathogen-derived antigens, a reduction in the dose of plasmid DNA, as well as an excellent safety profile. ICA614 Nanotaxi® represents a crucial step in DNA vaccine development, and is currently being tested by major vaccine companies (Sanofi-Pasteur, Merial etc.).

- mRNA Vaccine

Some other ICA Nanotaxi® are also being assessed in \$33.1 million RN-ARMORVAX consortium, co-funded by US Defense Advanced Research Projects Agency (DARPA). The consortium would validate the new application of ICA Nanotaxi® for mRNA-based vaccines for infectious diseases in collaboration with CureVac and Sanofi-Pasteur.

3. ICAFectin® transfection reagents

ICAFectin® transfection reagents are innovative breakthrough synthetic vectors for in vitro nucleic acid delivery. They are becoming the reagents of choice for efficient DNA and siRNA transfections as demonstrated by their increasing use in numerous studies published in high impact factor journals including Journal of Biological Chemistry, Nucleic Acids Research, PLOS ONE, PLOS Pathogen, Human Gene Therapy, Journal of Neurochemistry, Experimental Cell Research, Neoplasia, EMBO J...

In-Cell-Art is a privately held company, which was founded in 2005. It is a member of the Atlanpole Biotherapies high-tech cluster of biotechnology companies in western France.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a

legally separate and independent entity (Please see www.deloitte.com/about for more detailed information).

Deloitte provides audit, tax, consulting, and financial advisory services to public and private customers from multiple industries. With a globally connected network of member firms in more than 150 countries, Deloitte brings world-class capabilities and high-quality service to customers, delivering the insights they need to address their most complex business challenges. Deloitte's approximately 200,000 professionals are committed to becoming the standard of excellence.

For further information please contact;

In-Cell-Art

Sohei Fukuyama, Business Development and Alliance Management

Tel: 33 (0)2 40 71 67 17

E-mail: sohei.fukuyama@incellart.com

Website : <http://www.incellart.com>